pantoprazole has been researched along with Stomach Ulcer in 49 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Stomach Ulcer: Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " pylori-positive patients with active gastric ulcer were randomized to receive pantoprazole (40 mg) (P) and two of three antibiotics: clarithromycin (500 mg) (C), metronidazole (500 mg) (M) or amoxicillin (1000 mg) (A)." | 9.10 | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003) |
| "Pantoprazole appears to be superior to ranitidine in gastric ulcer healing." | 9.08 | Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. ( Hotz, J; Plein, K; Rose, K; Schönekäs, H, 1995) |
| "The proton pump inhibitors pantoprazole and omeprazole were compared in a randomized, double-blind study in 219 patients with benign gastric ulcers." | 9.08 | Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. ( Gütz, H; Hüttemann, W; Schepp, W; Witzel, L, 1995) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 9.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "The efficacy and safety of pantoprazole in the treatment of duodenal and gastric ulcers has been compared with that of the first proton pump inhibitor omeprazole in two (previously reported) clinical studies." | 8.79 | A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole. ( Rehner, M; Schepp, W; Witzel, L, 1994) |
| " pylori-positive patients with active gastric ulcer were randomized to receive pantoprazole (40 mg) (P) and two of three antibiotics: clarithromycin (500 mg) (C), metronidazole (500 mg) (M) or amoxicillin (1000 mg) (A)." | 5.10 | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003) |
| "5) with rheumatoid arthritis or osteoarthritis, requiring chronic intake of NSAIDs (at least 8 weeks prior to the start of the study), were randomised and enrolled to receive either 40 mg pantoprazole (n=70) or placebo (n=34) once daily, for 12 weeks." | 5.09 | Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. ( Bianchi Porro, G; Imbesi, V; Lazzaroni, M; Montrone, F; Santagada, T, 2000) |
| "Pantoprazole appears to be superior to ranitidine in gastric ulcer healing." | 5.08 | Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. ( Hotz, J; Plein, K; Rose, K; Schönekäs, H, 1995) |
| "The proton pump inhibitors pantoprazole and omeprazole were compared in a randomized, double-blind study in 219 patients with benign gastric ulcers." | 5.08 | Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. ( Gütz, H; Hüttemann, W; Schepp, W; Witzel, L, 1995) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 5.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| " Although PPIs have been introduced into the therapy of acute peptic ulcer disease at different daily, oral doses of 20 mg (omeprazole and rabeprazole), 30 mg (lansoprazole) and 40 mg (pantoprazole), the data suggest that the optimal dose of lansoprazole, omeprazole and pantoprazole, with respect to the acute treatment of peptic ulcers and moderate to severe gastroesophageal reflux disease (GERD), is about 30-40 mg daily." | 4.80 | Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. ( Horbach, S; Kromer, W; Lühmann, R, 1999) |
| "The clinical efficacy of the proton pump inhibitor pantoprazole has been compared with ranitidine in a number of clinical studies in patients with either duodenal or gastric ulcer(s) or gastro-oesophageal reflux disease." | 4.79 | Clinical efficacy of pantoprazole compared with ranitidine. ( Bader, JP; Delchier, JC, 1994) |
| "The efficacy and safety of pantoprazole in the treatment of duodenal and gastric ulcers has been compared with that of the first proton pump inhibitor omeprazole in two (previously reported) clinical studies." | 4.79 | A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole. ( Rehner, M; Schepp, W; Witzel, L, 1994) |
| "omeprazole was 6." | 2.74 | Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Shah, AH; Sodhi, JS; U-Saif, R; Yatoo, GN; Zargar, SA, 2009) |
| " Intravenous pantoprazole is especially distinguished in its lack of clinically relevant drug interactions, and it requires no dosage adjustment for patients with renal insufficiency or with mild to moderate hepatic dysfunction." | 2.41 | Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. ( Metz, DC, 2000) |
| "Pantoprazole has similar efficacy to other PPIs in the healing of gastric and duodenal ulcers, as well as erosive esophagitis, and as part of triple-drug regimens for the eradication of Helicobacter pylori from the gastric mucosa." | 2.41 | Pantoprazole: a new proton pump inhibitor. ( Jungnickel, PW, 2000) |
| "Pantoprazole is an irreversible proton pump inhibitor which, at the therapeutic dose of 40mg, effectively reduces gastric acid secretion." | 2.39 | Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. ( Fitton, A; Wiseman, L, 1996) |
| "Crocin is a novel agent that has potential in the prevention of ulceration induced by NSAIDs." | 1.43 | Protective activity of crocin against indomethacin-induced gastric lesions in rats. ( Ahmadi, I; Khani, MZ; Mard, SA; Mojahedin, S; Neisi, N; Pipelzadeh, MH; Teimoori, A, 2016) |
| "Pantoprazole is an irreversible proton pump inhibitor that is administered as a racemic mixture clinically." | 1.33 | Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs. ( Cao, H; Hu, ZQ; Ikejima, T; Sun, LX; Wang, MW; Zhao, WH, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (28.57) | 18.2507 |
| 2000's | 29 (59.18) | 29.6817 |
| 2010's | 5 (10.20) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Iliev, IE | 1 |
| Loidl, A | 1 |
| Alhazzani, W | 1 |
| Guyatt, G | 1 |
| Alshahrani, M | 1 |
| Deane, AM | 1 |
| Marshall, JC | 1 |
| Hall, R | 1 |
| Muscedere, J | 1 |
| English, SW | 1 |
| Lauzier, F | 1 |
| Thabane, L | 1 |
| Arabi, YM | 1 |
| Karachi, T | 1 |
| Rochwerg, B | 1 |
| Finfer, S | 1 |
| Daneman, N | 1 |
| Alshamsi, F | 1 |
| Zytaruk, N | 1 |
| Heel-Ansdell, D | 1 |
| Cook, D | 1 |
| Lenz, K | 1 |
| Buder, R | 1 |
| Firlinger, F | 1 |
| Lohr, G | 1 |
| Voglmayr, M | 1 |
| Mard, SA | 1 |
| Pipelzadeh, MH | 1 |
| Teimoori, A | 1 |
| Neisi, N | 1 |
| Mojahedin, S | 1 |
| Khani, MZ | 1 |
| Ahmadi, I | 1 |
| Wagener, M | 1 |
| Yüksel, I | 1 |
| Ataseven, H | 1 |
| Köklü, S | 1 |
| Ertuğrul, I | 1 |
| Başar, O | 1 |
| Odemiş, B | 1 |
| Ibiş, M | 1 |
| Saşmaz, N | 1 |
| Sahin, B | 1 |
| Fornai, M | 1 |
| Colucci, R | 1 |
| Antonioli, L | 1 |
| Ghisu, N | 1 |
| Tuccori, M | 1 |
| Blandizzi, C | 1 |
| Del Tacca, M | 1 |
| Oh, TH | 2 |
| Jung, HY | 1 |
| Choi, KD | 1 |
| Lee, GH | 1 |
| Song, HJ | 1 |
| Choi, KS | 1 |
| Chung, JW | 1 |
| Byeon, JS | 1 |
| Myung, SJ | 1 |
| Yang, SK | 1 |
| Kim, JH | 1 |
| Pellicano, R | 1 |
| Sharova, EP | 1 |
| Tan, VP | 1 |
| Wong, BC | 1 |
| Javid, G | 1 |
| Zargar, SA | 1 |
| U-Saif, R | 1 |
| Khan, BA | 1 |
| Yatoo, GN | 1 |
| Shah, AH | 1 |
| Gulzar, GM | 1 |
| Sodhi, JS | 1 |
| Khan, MA | 1 |
| Cho, SW | 1 |
| Hwang, JT | 1 |
| Wu, XP | 1 |
| He, JR | 1 |
| Wang, CL | 1 |
| Ling, QH | 1 |
| Hiramoto, JS | 1 |
| Terdiman, JP | 1 |
| Norton, JA | 1 |
| Malfertheiner, P | 1 |
| Kirchner, T | 1 |
| Kist, M | 1 |
| Leodolter, A | 1 |
| Peitz, U | 1 |
| Strobel, S | 1 |
| Bohuschke, M | 1 |
| Gatz, G | 1 |
| Boixeda, D | 1 |
| Martín De Argila, C | 1 |
| Bermejo, F | 1 |
| López Sanromán, A | 1 |
| Hernández Ranz, F | 1 |
| García Plaza, A | 1 |
| Shah, PJ | 1 |
| Gandhi, MS | 1 |
| Shah, MB | 1 |
| Goswami, SS | 1 |
| Santani, D | 1 |
| Enns, R | 1 |
| Cao, H | 1 |
| Wang, MW | 1 |
| Sun, LX | 1 |
| Ikejima, T | 1 |
| Hu, ZQ | 1 |
| Zhao, WH | 1 |
| Gawrońska-Szklarz, B | 1 |
| Wrześniewska, J | 1 |
| Starzyńska, T | 1 |
| Pawlik, A | 1 |
| Safranow, K | 1 |
| Ferenc, K | 1 |
| Droździk, M | 1 |
| Cheon, JH | 1 |
| Kim, SG | 1 |
| Kim, JM | 1 |
| Kim, N | 1 |
| Lee, DH | 1 |
| Kim, JS | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Ziemniak, W | 1 |
| Raffin, RP | 2 |
| Colomé, LM | 2 |
| Haas, SE | 1 |
| Jornada, DS | 1 |
| Pohlmann, AR | 2 |
| Guterres, SS | 2 |
| Oh, JH | 1 |
| Choi, MG | 1 |
| Dong, MS | 1 |
| Park, JM | 1 |
| Paik, CN | 1 |
| Cho, YK | 1 |
| Jeong, JJ | 1 |
| Lee, IS | 1 |
| Kim, SW | 1 |
| Han, SW | 1 |
| Choi, KY | 1 |
| Chung, IS | 1 |
| Pakhomova, IG | 1 |
| Hotz, J | 1 |
| Plein, K | 1 |
| Schönekäs, H | 1 |
| Rose, K | 1 |
| Witzel, L | 2 |
| Gütz, H | 1 |
| Hüttemann, W | 1 |
| Schepp, W | 2 |
| Adamek, RJ | 1 |
| Szymanski, C | 1 |
| Pfaffenbach, B | 1 |
| Opferkuch, W | 1 |
| Ricken, D | 1 |
| Wegener, M | 1 |
| Bader, JP | 1 |
| Delchier, JC | 1 |
| Rehner, M | 1 |
| Brunner, G | 1 |
| Harke, U | 1 |
| Fitton, A | 1 |
| Wiseman, L | 1 |
| Glaser, J | 1 |
| Hein, J | 1 |
| Daikeler, R | 1 |
| Weithofer, G | 1 |
| Vieth, M | 1 |
| Schmidt, M | 1 |
| Stolte, M | 1 |
| Treiber, G | 1 |
| Lambert, JR | 1 |
| Bardhan, KD | 1 |
| Morton, D | 1 |
| Slater, DN | 1 |
| Perry, MJ | 1 |
| Cherian, P | 1 |
| Jones, RB | 1 |
| Brookes, A | 1 |
| Thompson, M | 1 |
| Morris, P | 1 |
| McCaldin, B | 1 |
| Cammarota, G | 1 |
| Papa, A | 1 |
| Cianci, R | 1 |
| Cannizzaro, O | 1 |
| Armuzzi, A | 1 |
| Gasbarrini, A | 1 |
| Addolorato, G | 1 |
| Gasbarrini, GB | 1 |
| Kromer, W | 2 |
| Horbach, S | 1 |
| Lühmann, R | 1 |
| Bustamante, M | 1 |
| Stollman, N | 1 |
| Bianchi Porro, G | 1 |
| Lazzaroni, M | 1 |
| Imbesi, V | 1 |
| Montrone, F | 1 |
| Santagada, T | 1 |
| Metz, DC | 1 |
| Jungnickel, PW | 1 |
| Bardou, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Gönne, S | 1 |
| Riedel, R | 1 |
| Postius, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients Pilot Trial[NCT03372707] | 100 participants (Actual) | Interventional | 2018-07-05 | Completed | |||
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for pantoprazole and Stomach Ulcer
| Article | Year |
|---|---|
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Evidence-based analysis: postoperative gastric bleeding: etiology and prevention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; D | 2003 |
Clinical efficacy of pantoprazole compared with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 1994 |
A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Double-Blind Metho | 1994 |
Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1996 |
Pantoprazole--a third proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Enzyme I | 1997 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; | 2000 |
Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastric Ac | 2000 |
Pantoprazole: a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
14 trials available for pantoprazole and Stomach Ulcer
| Article | Year |
|---|---|
Withholding Pantoprazole for Stress Ulcer Prophylaxis in Critically Ill Patients: A Pilot Randomized Clinical Trial and Meta-Analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clostridium Infections; Critical Illness; Doub | 2017 |
Intermittent versus continuous pantoprazole infusion in peptic ulcer bleeding: a prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 2008 |
Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Drug Administratio | 2009 |
Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Be | 2003 |
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacteri | 2006 |
Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2006 |
Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2007 |
[Use of pantoprazol for treatment of gastroesophageal reflux disease and NSAID-induced gastropathy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Ster | 2007 |
Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Benzimidazoles; Double-Blind Method; Drug Ad | 1995 |
Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 | 1995 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Biopsy; Clarithrom | 1995 |
Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enterochromaffin Cells; Eso | 1994 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2000 |
22 other studies available for pantoprazole and Stomach Ulcer
| Article | Year |
|---|---|
A 61-Year-Old Woman with Chronic Iron-Deficiency Anemia Due to a Cameron Lesion and a Response to Oral Application of Combined Poloxamer 407 with Hyaluronic Acid and Chondroitin Sulfate Following Single Treatment with Pantoprazole: A Case Report.
Topics: Adjuvants, Immunologic; Anemia, Iron-Deficiency; Chondroitin Sulfates; Chronic Disease; Drug Carrier | 2021 |
Effect of proton pump inhibitors on gastric pH in patients exposed to severe stress.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastric Acid; Gastric Acidity Determination; | 2015 |
Protective activity of crocin against indomethacin-induced gastric lesions in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carotenoi | 2016 |
Haemotoxic snakebite in rural KwaZulu-Natal, South Africa: A case presenting with haematemesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Antivenins; Crystalloid Solutions | 2016 |
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroid | 2009 |
Degree of healing and healing-associated factors of endoscopic submucosal dissection-induced ulcers after pantoprazole therapy for 4 weeks.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Adenoma; Aged; Aged, 80 and over; Anti-Ulce | 2009 |
[Preparation sanpraz (pantoprazole): experience of application in treatment of gastroesophageal reflux disease and other acid related diseases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Gastric Aci | 2008 |
Management of acute peptic ulcers: how ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Asian People; Drug Administration Sch | 2009 |
Education and imaging. Gastrointestinal: Scrub typhus induced acute gastric ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Acute Disease; Aged; Anti-Bacterial Agents; | 2010 |
[Effect of pantoprazole on non-variceal bleeding].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; F | 2000 |
[Patient with increased stomach cancer risk. Helicobacter can cause damage here].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2002 |
Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Study of Mimusops elengi bark in experimental gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Anti-Ulcer Agents; Benzimida | 2003 |
Less acid + less bleeding = better outcomes and more money!
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pe | 2005 |
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2005 |
Development of HPMC and Eudragit S100 blended microparticles containing sodium pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acrylic Resins; Animals; Anti-Ulcer Agents; Calorimetry, Di | 2007 |
Enteric controlled-release pantoprazole-loaded microparticles prepared by using Eudragit S100 and poly(epsilon-caprolactone) blend.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetone; Administration, Oral; Animals; Anti-Ulcer Agents; | 2007 |
[Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1998 |
Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Pantoprazole (Protonix).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Dose-Response Rel | 2000 |
Direct comparison between the ulcer-healing effects of two H(+)-K(+)-ATPase inhibitors, one M1-selective antimuscarinic and one H2 receptor antagonist in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benz | 1990 |